Psychedelic compounds hold promise for alleviating human suffering. Initial trials of psychedelic-assisted treatments have established feasibility and safety, generating calls for replications. Meanwhile, social and medical sciences have drawn criticism due to perceptions of replication failures and varying public trust in empiricism. Data suggest that researchers and the public frequently misunderstand some of the statistical issues associated with replication, potentially leading to unrealistic expectations of treatment effects. Promoting discourse on what constitutes sufficient replication is especially warranted considering the ongoing progression of multi-site phase II and III clinical trials. Here, we review recent and classic work on prediction intervals and power analysis to reveal that trials of psychedelic-assisted therapy that emphasize statistical significance will likely include failures to replicate, especially if sample sizes do not increase dramatically. The field and the public should expect some failed replication attempts based on sampling variability alone. Continued emphasis on statistical significance will require markedly larger samples than those used in clinical trials to date, necessitating substantially greater resources. An alternative approach focused on prediction intervals has distinct advantages. We focus on a recent trial of MDMA-assisted therapy for PTSD to show that, based on prediction intervals, reasonable replications are well within reach. A lack of attention to these statistical issues could unnecessarily prompt widespread dismissal of these therapies before the intervention receives adequate investigation and a fair assessment. In contrast, realistic expectations and appropriate planning could help ensure that these treatments receive the opportunity to help those most in need.
{"title":"Reasonable expectations for replications of psychedelic-assisted therapy: The case for prediction intervals rather than P-values","authors":"M. Earleywine, Philip Kamilar-Britt","doi":"10.1556/2054.2022.00219","DOIUrl":"https://doi.org/10.1556/2054.2022.00219","url":null,"abstract":"\u0000 Psychedelic compounds hold promise for alleviating human suffering. Initial trials of psychedelic-assisted treatments have established feasibility and safety, generating calls for replications. Meanwhile, social and medical sciences have drawn criticism due to perceptions of replication failures and varying public trust in empiricism. Data suggest that researchers and the public frequently misunderstand some of the statistical issues associated with replication, potentially leading to unrealistic expectations of treatment effects. Promoting discourse on what constitutes sufficient replication is especially warranted considering the ongoing progression of multi-site phase II and III clinical trials. Here, we review recent and classic work on prediction intervals and power analysis to reveal that trials of psychedelic-assisted therapy that emphasize statistical significance will likely include failures to replicate, especially if sample sizes do not increase dramatically. The field and the public should expect some failed replication attempts based on sampling variability alone. Continued emphasis on statistical significance will require markedly larger samples than those used in clinical trials to date, necessitating substantially greater resources. An alternative approach focused on prediction intervals has distinct advantages. We focus on a recent trial of MDMA-assisted therapy for PTSD to show that, based on prediction intervals, reasonable replications are well within reach. A lack of attention to these statistical issues could unnecessarily prompt widespread dismissal of these therapies before the intervention receives adequate investigation and a fair assessment. In contrast, realistic expectations and appropriate planning could help ensure that these treatments receive the opportunity to help those most in need.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46221929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thais Guimarães Bourscheid, Leonardo Corrêa Cardoso, Marcelo Henrique Nascimento Santana, Letícia Cimó de Oliveira, F. Z. Reginato, M. Machado, André Valle de Bairros
Snuff is a fine aromatic powder composed of dried and thin leaves combined with tobacco, roots, peels, and seeds. Its use for indigenous religious purposes has appeared since pre-Columbian period in various localities of American continent. Practice is considered sacred in indigenous culture and suffered from trivialization of consumption due to influence of colonizers, which triggered subsequent industrialization of this complex for commercial purposes. Commercial snuff is essentially made from industrialized tobacco without addition of other medicinal plants and without therapeutic or spiritual purposes beyond its indiscriminate and inappropriate use, causing health risks. Therefore, this study aimed to make a review on snuff in Brazilian culture and a tour of a local community. In shamanism, plants are used as access vehicles to other religions of cosmos and its inhabitants, from where experts dialogue, bring songs, news, omens, and acquire new knowledge. The plants used in shamanic composition of snuff vary with the locality of indigenous villages in America and are essential ingredients of this interaction between humans and non-humans, a special mediator of intersubjective interactions. Several studies show the use and meaning of Erythroxylum coca used in different communities of the Amazon, besides Chacrona and Mariri, popular names of plants used in manufacture of Ayahuasca drink by doctrine Santo Daime. Because of this, it is essential to establish differences between recreational snuff and shamanic and their effects on body as well as studies on use of shamanic snuff should be directed according to their applications and plants employed by communities.
{"title":"Use of snuff and its main constituents for religious purposes in an alternative community with shamanic practices in the south of Brazil","authors":"Thais Guimarães Bourscheid, Leonardo Corrêa Cardoso, Marcelo Henrique Nascimento Santana, Letícia Cimó de Oliveira, F. Z. Reginato, M. Machado, André Valle de Bairros","doi":"10.1556/2054.2022.00220","DOIUrl":"https://doi.org/10.1556/2054.2022.00220","url":null,"abstract":"\u0000 Snuff is a fine aromatic powder composed of dried and thin leaves combined with tobacco, roots, peels, and seeds. Its use for indigenous religious purposes has appeared since pre-Columbian period in various localities of American continent. Practice is considered sacred in indigenous culture and suffered from trivialization of consumption due to influence of colonizers, which triggered subsequent industrialization of this complex for commercial purposes. Commercial snuff is essentially made from industrialized tobacco without addition of other medicinal plants and without therapeutic or spiritual purposes beyond its indiscriminate and inappropriate use, causing health risks. Therefore, this study aimed to make a review on snuff in Brazilian culture and a tour of a local community. In shamanism, plants are used as access vehicles to other religions of cosmos and its inhabitants, from where experts dialogue, bring songs, news, omens, and acquire new knowledge. The plants used in shamanic composition of snuff vary with the locality of indigenous villages in America and are essential ingredients of this interaction between humans and non-humans, a special mediator of intersubjective interactions. Several studies show the use and meaning of Erythroxylum coca used in different communities of the Amazon, besides Chacrona and Mariri, popular names of plants used in manufacture of Ayahuasca drink by doctrine Santo Daime. Because of this, it is essential to establish differences between recreational snuff and shamanic and their effects on body as well as studies on use of shamanic snuff should be directed according to their applications and plants employed by communities.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41714193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ada Kałużna, M. Schlosser, Emily Gulliksen Craste, Jack Stroud, James Cooke
Despite promising findings indicating the therapeutic potential of psychedelic experience across a variety of domains, the mechanisms and factors affecting its efficacy remain unclear. The present paper explores this by focusing on two psychedelic states which have been suggested as therapeutically significant in past literature: ego-dissolution and connectedness. The aim of the study is to investigate the impact of ego-dissolution and connectedness on the therapeutic effects of the psychedelic experience. The investigation was carried out as a mixed methods systematic review, with the data from four databases analysed thematically and results presented through narrative synthesis. The analysis and synthesis of findings from 15 unique studies (n = 2,182) indicated that both ego-dissolution and connectedness are associated with a higher chance of improvement following a psychedelic experience. However, there seem to be differences in the way the two experiences affect individuals psychologically. Ego-dissolution appears to trigger psychological change but does not typically exceed the psychedelic experience in its duration, while connectedness can be more sustained and is associated with several positive, potentially therapeutic feelings. Moreover, the findings of this review have implications for further theory-building about the mechanisms which enable therapeutic effects in psychedelic experience. This in turn might lead to improved models for psychedelic therapy practice. Emphasis on ego-dissolution during the preparation phase and on connectedness during integration is one suggestion presented here, alongside overarching implications for the mental health debate and general practice.
{"title":"Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience","authors":"Ada Kałużna, M. Schlosser, Emily Gulliksen Craste, Jack Stroud, James Cooke","doi":"10.1556/2054.2022.00199","DOIUrl":"https://doi.org/10.1556/2054.2022.00199","url":null,"abstract":"\u0000 \u0000 \u0000 Despite promising findings indicating the therapeutic potential of psychedelic experience across a variety of domains, the mechanisms and factors affecting its efficacy remain unclear. The present paper explores this by focusing on two psychedelic states which have been suggested as therapeutically significant in past literature: ego-dissolution and connectedness. The aim of the study is to investigate the impact of ego-dissolution and connectedness on the therapeutic effects of the psychedelic experience.\u0000 \u0000 \u0000 \u0000 The investigation was carried out as a mixed methods systematic review, with the data from four databases analysed thematically and results presented through narrative synthesis.\u0000 \u0000 \u0000 \u0000 The analysis and synthesis of findings from 15 unique studies (n = 2,182) indicated that both ego-dissolution and connectedness are associated with a higher chance of improvement following a psychedelic experience. However, there seem to be differences in the way the two experiences affect individuals psychologically. Ego-dissolution appears to trigger psychological change but does not typically exceed the psychedelic experience in its duration, while connectedness can be more sustained and is associated with several positive, potentially therapeutic feelings.\u0000 \u0000 \u0000 \u0000 Moreover, the findings of this review have implications for further theory-building about the mechanisms which enable therapeutic effects in psychedelic experience. This in turn might lead to improved models for psychedelic therapy practice. Emphasis on ego-dissolution during the preparation phase and on connectedness during integration is one suggestion presented here, alongside overarching implications for the mental health debate and general practice.\u0000","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42439288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ayahuasca's psychological and subjective effects were compared in rituals of two neoshamanic groups in Uruguay. Compare, describe and analyze psychological effects and subjective experiences of ayahuasca ceremonies in two different groups: a psychospiritual holistic center, and a center specialized in substance use disorder's treatment. A mixed qualitative-quantitative study was conducted, using the Hallucinogen Rating Scale for measuring psychological effects, and in-depth interviews for the description of ayahuasca subjective experiences. Data from both techniques were compared, analyzing convergences and differences. When comparing the two neoshamanic groups, significant differences with a medium-size effect were found in the psychological variables Affect (r = 0.47), Cognition (r = 0.36) and Perception (r = 0.36). The qualitative descriptions of ayahuasca experiences in the group with higher scores in those variables showed more frequent and complex experiences of emotional, cognitive, and perceptive content. Dissimilar results were found when comparing Intensity and Somaesthetic domains, with no significant results in the quantitative part, while in the qualitative part intensity was reported as “soft” in one group, and corporal experiences (e.g., purging effects) were especially manifested. Stronger subjective experiences and higher psychological effects may be related to differences in the dosage and the setting of the centers. Emotional, cognitive, and perceptive psychological effects of ayahuasca rituals measured by the Hallucinogen Rating Scale, seem to be associated with more frequent and complex subjective experiences in the mentioned domains. Qualitative group differences in corporal alterations and the overall intensity of the experience differed from non-significant results of the quantitative part of the study.
{"title":"Psychological effects and subjective experiences of ayahuasca rituals in participants of two neoshamanic centers of Uruguay","authors":"Ismael Apud, Juan Scuro, I. Carrera, A. Oliveri","doi":"10.1556/2054.2022.00202","DOIUrl":"https://doi.org/10.1556/2054.2022.00202","url":null,"abstract":"\u0000 \u0000 \u0000 Ayahuasca's psychological and subjective effects were compared in rituals of two neoshamanic groups in Uruguay.\u0000 \u0000 \u0000 \u0000 Compare, describe and analyze psychological effects and subjective experiences of ayahuasca ceremonies in two different groups: a psychospiritual holistic center, and a center specialized in substance use disorder's treatment.\u0000 \u0000 \u0000 \u0000 A mixed qualitative-quantitative study was conducted, using the Hallucinogen Rating Scale for measuring psychological effects, and in-depth interviews for the description of ayahuasca subjective experiences. Data from both techniques were compared, analyzing convergences and differences.\u0000 \u0000 \u0000 \u0000 When comparing the two neoshamanic groups, significant differences with a medium-size effect were found in the psychological variables Affect (r = 0.47), Cognition (r = 0.36) and Perception (r = 0.36). The qualitative descriptions of ayahuasca experiences in the group with higher scores in those variables showed more frequent and complex experiences of emotional, cognitive, and perceptive content. Dissimilar results were found when comparing Intensity and Somaesthetic domains, with no significant results in the quantitative part, while in the qualitative part intensity was reported as “soft” in one group, and corporal experiences (e.g., purging effects) were especially manifested.\u0000 \u0000 \u0000 \u0000 Stronger subjective experiences and higher psychological effects may be related to differences in the dosage and the setting of the centers. Emotional, cognitive, and perceptive psychological effects of ayahuasca rituals measured by the Hallucinogen Rating Scale, seem to be associated with more frequent and complex subjective experiences in the mentioned domains. Qualitative group differences in corporal alterations and the overall intensity of the experience differed from non-significant results of the quantitative part of the study.\u0000","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48849297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John M Clifton, Annabelle M Belcher, Aaron D Greenblatt, Christopher M Welsh, Thomas O Cole, Alan K Davis
Background and aims: There is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst a cohort of Black individuals diagnosed with OUD.
Methods: Using a convenience sampling approach, patients were recruited from an urban methadone treatment program and paid five dollars to complete an anonymous phone-based survey.
Results: Twenty-eight patients participated (mean age 53.8; N = 28; 35.7% female). Most (N = 23; 82.1%) had "heard of" psilocybin mushrooms before taking the survey, but only five (N = 5; 17.8%) had ever used them. More than 80% perceived a risk or were "unsure" of the risk for sixteen of the seventeen items queried about psilocybin. Approximately half (N = 15; 53.6%) were willing to try therapy incorporating psilocybin and half (N = 14; 50%) said they would be more likely to try if it were FDA approved for OUD. Most (N = 18; 64.3%) preferred to stay on methadone treatment alone, 32.1% (N = 9) wanted to try treatment with both psilocybin and methadone, and only one participant opted for psilocybin treatment without methadone.
Conclusion: Many Black individuals with Opioid Use Disorder perceive psilocybin as dangerous and may be hesitant to try psilocybin treatment. Culturally informed treatment models, educational interventions and community outreach programs should be developed to increase racial/ethnic minority representation in psilocybin research and treatment.
{"title":"Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder.","authors":"John M Clifton, Annabelle M Belcher, Aaron D Greenblatt, Christopher M Welsh, Thomas O Cole, Alan K Davis","doi":"10.1556/2054.2022.00214","DOIUrl":"https://doi.org/10.1556/2054.2022.00214","url":null,"abstract":"<p><strong>Background and aims: </strong>There is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst a cohort of Black individuals diagnosed with OUD.</p><p><strong>Methods: </strong>Using a convenience sampling approach, patients were recruited from an urban methadone treatment program and paid five dollars to complete an anonymous phone-based survey.</p><p><strong>Results: </strong>Twenty-eight patients participated (mean age 53.8; <i>N</i> = 28; 35.7% female). Most (<i>N</i> = 23; 82.1%) had \"heard of\" psilocybin mushrooms before taking the survey, but only five (<i>N</i> = 5; 17.8%) had ever used them. More than 80% perceived a risk or were \"unsure\" of the risk for sixteen of the seventeen items queried about psilocybin. Approximately half (<i>N</i> = 15; 53.6%) were willing to try therapy incorporating psilocybin and half (<i>N</i> = 14; 50%) said they would be more likely to try if it were FDA approved for OUD. Most (<i>N</i> = 18; 64.3%) preferred to stay on methadone treatment alone, 32.1% (<i>N</i> = 9) wanted to try treatment with both psilocybin and methadone, and only one participant opted for psilocybin treatment without methadone.</p><p><strong>Conclusion: </strong>Many Black individuals with Opioid Use Disorder perceive psilocybin as dangerous and may be hesitant to try psilocybin treatment. Culturally informed treatment models, educational interventions and community outreach programs should be developed to increase racial/ethnic minority representation in psilocybin research and treatment.</p>","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/1b/nihms-1863083.PMC9850635.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10611232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Little is known about individual differences in Hallucinogen Persisting Perceptual Disorder (HPPD). This study investigated visual processing style and personality across two HPPD types (HPPD I and HPPD II) and a Non-HPPD group. An online survey was delivered to participants sourced from online HPPD and psychedelic user groups and forums (N = 117). Using one-way ANOVA, respondents were compared across four measures of individual difference. Using logistic regression, a range of visual symptoms and experiences were investigated as potential predictors of group categorisation. The HPPD I group had higher absorption and visual apophenia scores than the other groups and was predicted by higher drug use. The HPPD II group showed significantly higher trait anxiety than both other groups. Across the HPPD groups, HPPD II categorisation was also predicted by increased negative precipitating experiences, lack of prior knowledge and pre-existing anxiety diagnoses. Anxiety, negative precipitating experiences and lack of prior knowledge are associated with negative experiences of persistent visual symptoms following hallucinogen use, whilst higher absorption and visual apophenia are associated with positive or neutral experiences. Together these findings indicate that differences in personality may play a role in determining an individual's experience of HPPD, highlighting the role of individual difference research in expanding knowledge around HPPD.
{"title":"Apophenia, absorption and anxiety: Evidence for individual differences in positive and negative experiences of Hallucinogen Persisting Perceptual Disorder","authors":"Alexander Irvine, D. Luke","doi":"10.1556/2054.2022.00195","DOIUrl":"https://doi.org/10.1556/2054.2022.00195","url":null,"abstract":"\u0000 \u0000 \u0000 Little is known about individual differences in Hallucinogen Persisting Perceptual Disorder (HPPD). This study investigated visual processing style and personality across two HPPD types (HPPD I and HPPD II) and a Non-HPPD group.\u0000 \u0000 \u0000 \u0000 An online survey was delivered to participants sourced from online HPPD and psychedelic user groups and forums (N = 117). Using one-way ANOVA, respondents were compared across four measures of individual difference. Using logistic regression, a range of visual symptoms and experiences were investigated as potential predictors of group categorisation.\u0000 \u0000 \u0000 \u0000 The HPPD I group had higher absorption and visual apophenia scores than the other groups and was predicted by higher drug use. The HPPD II group showed significantly higher trait anxiety than both other groups. Across the HPPD groups, HPPD II categorisation was also predicted by increased negative precipitating experiences, lack of prior knowledge and pre-existing anxiety diagnoses.\u0000 \u0000 \u0000 \u0000 Anxiety, negative precipitating experiences and lack of prior knowledge are associated with negative experiences of persistent visual symptoms following hallucinogen use, whilst higher absorption and visual apophenia are associated with positive or neutral experiences. Together these findings indicate that differences in personality may play a role in determining an individual's experience of HPPD, highlighting the role of individual difference research in expanding knowledge around HPPD.\u0000","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43109703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this opinion piece we propose the investigation of psychedelic-assisted psychotherapy for the treatment of body dysmorphic disorder (BDD). BDD is a psychiatric disorder characterised by appearance-based preoccupations and accompanying compulsions. While safe and effective treatments for BDD exist, non-response and relapse rates remain high. Therefore, there is a need to investigate promising new treatment options for this highly debilitating condition. Preliminary evidence suggests safety, feasibility, and potential efficacy of psychedelic treatments in disorders that share similar psychopathological mechanisms with BDD. Drawing on this evidence, as well as on relevant qualitative reports and theoretical proposals, we argue that it would be worthwhile to conduct a phase 2a study aimed at assessing the safety and feasibility of psychedelic-assisted psychotherapy in BDD. We also offer some suggestions for how future research ought to proceed.
{"title":"Psychedelic therapy for body dysmorphic disorder","authors":"Shevaugn Johnson, Chris Letheby","doi":"10.1556/2054.2022.00200","DOIUrl":"https://doi.org/10.1556/2054.2022.00200","url":null,"abstract":"\u0000 In this opinion piece we propose the investigation of psychedelic-assisted psychotherapy for the treatment of body dysmorphic disorder (BDD). BDD is a psychiatric disorder characterised by appearance-based preoccupations and accompanying compulsions. While safe and effective treatments for BDD exist, non-response and relapse rates remain high. Therefore, there is a need to investigate promising new treatment options for this highly debilitating condition. Preliminary evidence suggests safety, feasibility, and potential efficacy of psychedelic treatments in disorders that share similar psychopathological mechanisms with BDD. Drawing on this evidence, as well as on relevant qualitative reports and theoretical proposals, we argue that it would be worthwhile to conduct a phase 2a study aimed at assessing the safety and feasibility of psychedelic-assisted psychotherapy in BDD. We also offer some suggestions for how future research ought to proceed.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42048839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The paper discusses the concepts of hallucination and psychedelic experience in philosophical and anthropological contexts, where these terms bring in presuppositions regarding body and soul, nature and culture. The discussion of the concepts is presented in the context of the debate between Viveiros de Castro's Amerindian perspectivism and Meillassoux's speculative materialism, where in the former the concepts have undergone an anthropological epoché in addressing the problematic presuppositions of unreality and in the latter hallucination and related concepts appear in a canonical western sense as imitations of the real. This debate appears to be closely related to the project of naturalization of spirituality. The critique also extends to concepts such as psychedelic and entheogen. In respect to certain indigenous concepts like kepigari of the Matsigenka, observed in anthropology (Shepard, 2018; Danowski, Viveiros de Castro, 2021) and by revisiting Derrida's Plato's Pharmacy (1981) we suggest that the philosopheme of pharmakon suits the role of proximity with indigenous thought for comparative analyses and offers a perspective for psychedelic philosophy. The suggestion of considering psychedelics as an existential medicine (Letheby, 2017) could be interpreted as offering a pharmakon with ambiguous, indeterminate possibilities which would emphasize its theoretical soundness.
本文讨论了哲学和人类学语境中的幻觉和迷幻体验的概念，这些术语带来了关于身体和灵魂、自然和文化的预设。这些概念的讨论是在维韦罗斯·德·卡斯特罗的美洲透视主义与梅拉索的思辨唯物主义之争的背景下提出的，在前者中，概念经历了一个人类学时代，以解决不真实性的有问题的预设，而在后者中，幻觉和相关概念在典型的西方意义上表现为对真实的模仿。这场辩论似乎与精神自然化项目密切相关。批判还延伸到了诸如迷幻和热情之类的概念。关于某些土著概念，如人类学中观察到的Matsigenka的kepigari（Shepard，2018；Danowski，Viveiros de Castro，2021），并通过重新审视德里达的《柏拉图的药学》（1981），我们认为pharmakon的哲学适合与土著思想接近的角色进行比较分析，并为迷幻哲学提供了一个视角。将迷幻药视为一种存在医学的建议（Letheby，2017）可以被解释为提供了一种具有模糊、不确定可能性的药物，这将强调其理论合理性。
{"title":"Of pharmakon: Hallucination in Amerindian perspectivism and speculative materialism","authors":"Ignas Šatkauskas","doi":"10.1556/2054.2022.00212","DOIUrl":"https://doi.org/10.1556/2054.2022.00212","url":null,"abstract":"\u0000 \u0000 \u0000 The paper discusses the concepts of hallucination and psychedelic experience in philosophical and anthropological contexts, where these terms bring in presuppositions regarding body and soul, nature and culture.\u0000 \u0000 \u0000 \u0000 The discussion of the concepts is presented in the context of the debate between Viveiros de Castro's Amerindian perspectivism and Meillassoux's speculative materialism, where in the former the concepts have undergone an anthropological epoché in addressing the problematic presuppositions of unreality and in the latter hallucination and related concepts appear in a canonical western sense as imitations of the real.\u0000 \u0000 \u0000 \u0000 This debate appears to be closely related to the project of naturalization of spirituality. The critique also extends to concepts such as psychedelic and entheogen. In respect to certain indigenous concepts like kepigari of the Matsigenka, observed in anthropology (Shepard, 2018; Danowski, Viveiros de Castro, 2021) and by revisiting Derrida's Plato's Pharmacy (1981) we suggest that the philosopheme of pharmakon suits the role of proximity with indigenous thought for comparative analyses and offers a perspective for psychedelic philosophy.\u0000 \u0000 \u0000 \u0000 The suggestion of considering psychedelics as an existential medicine (Letheby, 2017) could be interpreted as offering a pharmakon with ambiguous, indeterminate possibilities which would emphasize its theoretical soundness.\u0000","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49284377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this literature from a broader biopsychosocial perspective. Examining these arguably neglected social and psychological aspects of psychedelic treatment can provide a more holistic understanding of the interplay between the interconnected domains. This review of six major clinical trials applies a biopsychosocial model to evaluate the antidepressant effects of psilocybin and ketamine assisted therapy. We conclude that combination psychedelic treatment and psychotherapy facilitate more enduring and profound antidepressant effects than produced by ketamine or psilocybin alone. Emphasising the advantages of therapeutic intervention will encourage those who may attempt to self-medicate with psychedelics to instead seek a framework of psychological support, minimising associated risks of unregulated use.
{"title":"Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions","authors":"A. McCartney, H. McGovern, Alexander De Foe","doi":"10.1556/2054.2022.00211","DOIUrl":"https://doi.org/10.1556/2054.2022.00211","url":null,"abstract":"\u0000 Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this literature from a broader biopsychosocial perspective. Examining these arguably neglected social and psychological aspects of psychedelic treatment can provide a more holistic understanding of the interplay between the interconnected domains. This review of six major clinical trials applies a biopsychosocial model to evaluate the antidepressant effects of psilocybin and ketamine assisted therapy. We conclude that combination psychedelic treatment and psychotherapy facilitate more enduring and profound antidepressant effects than produced by ketamine or psilocybin alone. Emphasising the advantages of therapeutic intervention will encourage those who may attempt to self-medicate with psychedelics to instead seek a framework of psychological support, minimising associated risks of unregulated use.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45570894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mystical experiences frequently precede decreases in human suffering or increased functioning. Therapies that include the ingestion of psychoactive substances in supportive environments often lead to improvements that correlate with the magnitude of the mystical experiences generated. A close look at these phenomena from a philosophy of science perspective might put empiricists in a quandary. Arguments with critics of the import of these mystical experiences, prohibitionists, or others who are apprehensive about psychedelic-assisted treatments, might prove awkward or difficult given the tacit assertion that the mystical genuinely exists. The assumption might even dampen theorizing in ways that remain outside of theorists' awareness. The predicament might lack the epistemic humility ideal for good science as well. Nevertheless, abandoning the construct of mystical experiences would require ignoring compelling, replicated empirical work. We argue that a version of philosophical fictionalism that draws on research in logic and linguistics can help investigators engage in this discourse without implying a belief in the mystical. Comparable approaches have proven helpful in mathematics and empiricism more broadly. Mystical fictionalism could help theorists view reports of mystical experiences as true even if the mystical fails to be veridical. The approach creates an expressive advantage that could assist researchers and theorists eager to refine our understanding of mystical experiences and improve psychedelic-assisted treatments. Mystical fictionalism might also inspire novel looks at correlates of mystical experiences that might serve as mediators of their effects, potentially generating models with comparable explanatory power that sidestep the need for a fictionalist approach.
{"title":"Mystical experiences without mysticism: An argument for mystical fictionalism in psychedelics","authors":"Bradley Armour Garb, M. Earleywine","doi":"10.1556/2054.2022.00207","DOIUrl":"https://doi.org/10.1556/2054.2022.00207","url":null,"abstract":"\u0000 Mystical experiences frequently precede decreases in human suffering or increased functioning. Therapies that include the ingestion of psychoactive substances in supportive environments often lead to improvements that correlate with the magnitude of the mystical experiences generated. A close look at these phenomena from a philosophy of science perspective might put empiricists in a quandary. Arguments with critics of the import of these mystical experiences, prohibitionists, or others who are apprehensive about psychedelic-assisted treatments, might prove awkward or difficult given the tacit assertion that the mystical genuinely exists. The assumption might even dampen theorizing in ways that remain outside of theorists' awareness. The predicament might lack the epistemic humility ideal for good science as well. Nevertheless, abandoning the construct of mystical experiences would require ignoring compelling, replicated empirical work. We argue that a version of philosophical fictionalism that draws on research in logic and linguistics can help investigators engage in this discourse without implying a belief in the mystical. Comparable approaches have proven helpful in mathematics and empiricism more broadly. Mystical fictionalism could help theorists view reports of mystical experiences as true even if the mystical fails to be veridical. The approach creates an expressive advantage that could assist researchers and theorists eager to refine our understanding of mystical experiences and improve psychedelic-assisted treatments. Mystical fictionalism might also inspire novel looks at correlates of mystical experiences that might serve as mediators of their effects, potentially generating models with comparable explanatory power that sidestep the need for a fictionalist approach.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44895355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：